in this issue
Regions :: Western Europe :: Germany
Lonza Joins DSM as Manufacturer of Biopharma Drug for Agennix
4:02 AM MDT | April 12, 2012 | Alex Scott
Lonza has agreed to supply Agennix (Heidelberg, Germany), a biotech firm, with commercial quantities of talactoferrin, Agennix’s trial drug for the treatment of non-small cell lung cancer (NSCLC). As part of the deal, Lonza will also develop a biotech process for manufacturing the drug. Financial terms were not disclosed. Talactoferrin is an oral Dendritic Cell Mediated Immunotherapy (DCMI) drug. It is the first drug candidate of its type and currently is in phase III trials for treating NSCLC. Lonza will manufacture commercial quantities of...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee